Short-term vagus nerve stimulation reduces myocardial apoptosis by downregulating microRNA-205 in rats with chronic heart failure

YANHUA XUAN1,2, SHUANGSHUANG LIU1, YAN LI3, JING DONG1, JIAYING LUO1, TAO LIU4, YUANZHE JIN2 and ZHIJUN SUN1

1Department of Cardiology Medicine, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110022; 2Department of Cardiology Medicine, Fourth Affiliated Hospital of China Medical University, Shenyang, Liaoning 110032; 3Department of Geriatrics, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110022; 4Department of Geriatrics, People's Hospital of Jilin City, Jilin 132000, P.R. China

Received July 11, 2016; Accepted July 11, 2017

DOI: 10.3892/mmr.2017.7344

Abstract. Previous studies have reported that short-term vagus nerve stimulation (VNS) improves cardiac function in rats with chronic heart failure (CHF). The molecular mechanisms are unclear. The potential effect of microRNA (miR)-205 in apoptosis of short-term VNS was examined. A total of 3 weeks after inducing CHF, the rats were divided into three groups: Sham stimulation in sham operated rats, sham stimulation in CHF rats (CHF-SS), and treated with VNS in CHF rats (CHF-VNS). The right vagus nerve of the neck was stimulated for 72 h in CHF rats with rectangular pulses of 40 msec duration at 1 Hz and 5 V. miR-205 was focused on, which exhibited differential expression in the miRNA microarray analysis of CHF rats, and the effects of VNS on apoptosis were examined. It was verified that the expression level of miR-205 in the CHF-SS group was increased, and the expression was reduced in the CHF-VNS group. Furthermore, mimics or inhibitor of miR-205 was transfected into H9c2 to investigate its function on apoptosis. Baculoviral IAP repeat-containing protein 2 (Birc2) was confirmed a target of miR-205 through a dual luciferase reporter assay and western blotting. It was demonstrated that downregulated miR-205 decreased apoptosis in H9c2 cells. The apoptosis-associated proteins were further detected in H9c2 cells and rat tissue. The mRNA and protein expression levels of caspase-3 and Bcl-2-associated X protein were decreased in the CHF-VNS group, the expression of Birc2 and B-cell lymphoma 2 were increased. The results were consistent with the in vitro study in the miR-205 inhibitor group. The present study demonstrated that short-term VNS decreased apoptosis by downregulating miR-205 in rats with CHF. Therefore, the results of the present study provide basic evidence for short-term VNS in the clinical treatment of CHF.

Introduction

Chronic heart failure (CHF) is the end stage of various cardiovascular diseases and poses a serious threat to human health, as it responds poorly to treatment (1). Previous clinical investigations demonstrated that long-term vagus nerve stimulation (VNS) therapy reduces ventricular remodeling and improves cardiac function, and increases exercise tolerance and the quality of life following CHF (2-4). Our previous study has demonstrated that short-term VNS also improves left ventricular function in rats with CHF (5). However, the molecular mechanisms of short-term VNS treatment remain unclear.

MicroRNAs (miRNAs/miRs) are highly conserved, endogenous, single-stranded non-coding small RNA molecules. miRNAs regulate gene expression by promoting degradation of target mRNA and (or) inhibiting translation. miRNAs involve cellular differentiation, proliferation, apoptosis and development processes of a variety of biological tissues (6). Previous studies have identified that specific miRNAs participate in the pathology of heart disease development, particularly in the progression of heart failure (HF) (7-10). Myocardial apoptosis is also involved in the development of HF (11,12). Reducing cardiac damage is a potential therapeutic target for HF (13). miRNAs are also essential for regulation of cardiomyocyte apoptosis (14,15).

Our earlier study hypothesized that miRNAs may be cardioprotective of short-term VNS in rats with CHF. Therefore, the differential expression of miRNAs was assessed using microarray analysis (16). The present study focused on miR-205, which was upregulated after the treatment with sham stimulation (SS) and downregulated after the treatment with short-term VNS following CHF in rats. In addition, the present study selected baculoviral IAP repeat-containing protein as a target of miR-205.
2 (Birc2), an inhibitor of apoptosis protein, as a predicted target gene of miR-205 through bioinformatics analysis. It was demonstrated that downregulated miR-205 increased Birc2 expression and reduced cardiac apoptosis in CHF rats.

Materials and methods

Rat model of CHF and VNS. The Animal Center of the Chinese Academy of Medical Sciences (Beijing, China) provided 58 male Wistar rats (7-8 weeks of age; weighing 250-300 g) to prepare the CHF model in the present study. The use of all rats was in strict compliance with the provisions of Animal Research Ethics Committee of Shengjing Hospital of China Medical University (Shenyang, Liaoning, China). The rats were kept in a stainless-steel net cage under standard laboratory conditions (25°C; relative humidity 60%; 12-h light/dark cycle) with free access to food and water. All animals were randomly divided into three groups: i) treated with SS in sham operated rats (SO-SS group, n=8), ii) treated with SS in CHF rats (CHF-SS group, n=8), and iii) treated with VNS in CHF rats (CHF-VNS group, n=8). As described previously, a thoracotomy was performed under 1% pellitobarbitalum natricum (40 mg/kg) anesthesia administered via an intraperitoneal injection. The left anterior descending coronary artery was ligated firmly with proline suture (Ethicon, Inc., Cincinnati, OH, USA) to produce myocardial infarction (17,18). The left anterior descending coronary artery was tied loosely in the SO-SS group. At 3 weeks after the myocardial infarction operation, echocardiography was performed on the surviving rats. The rats with an infarction area >40% of the left ventricular wall area were enrolled for research (5). This method of research was approved by the ethics committee of Shengjing Hospital of China Medical University (Shenyang, Liaoning, China).

As described in our previous study (5), a pair of Teflon-coated stainless steel wires (UL1330; Triumph Cable Co., Ltd., Dongguan, Guangdong, China) was looped around the right vagus nerve in the neck for electrical stimulation. The wires were connected to the output terminals of the stimulator (BL-420S Data Acquisition & Analysis System; Chengdu Tme Technology Co, Ltd., Chengdu, Sichuan, China). Rectangular waves were connected to the output terminals of the stimulator (BL-420S Data Acquisition & Analysis System; Chengdu Tme Technology Co, Ltd., Chengdu, Sichuan, China). Rectangular pulses were used at 1 Hz, 5 V and 40 msec duration for 72 h to stimulate the vagus nerve.

Cardiac tissue preparation. The rats were sacrificed following 72 h of treatment. For each rat, the whole heart tissue was rapidly excised and washed with cold phosphate buffer. Heart tissues were frozen at -80°C for reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and western blot analysis.

Cell culture. The H9c2 rat myoblasts and 293T human renal epithelial cells (Cell Bank of the Chinese Academy of Sciences, Shanghai, China) were cultured in Dulbecco’s modified Eagle’s medium (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) containing 10% (v/v) FBS (Hyclone; GE Healthcare Life Sciences, Logan, UT, USA) at 37°C in a mixed atmosphere of 5% CO₂ and 95% air.

Cell transfection. Cell transfection was carried out using Attractene Transfection reagent (Qiagen GmbH, Hilden, Germany) following the manufacturer’s protocol. miR-205 mimics (miR-205m), miR-205 inhibitor (miR-205i), and matched negative controls (NCm, negative control mimics; NCi, negative control inhibitor) were synthesized by GE Healthcare Dharmacon, Inc. (Lafayette, CO, USA). The level of miRNA expression in the cells was assayed by RT-qPCR.

miRNA microarray analysis. The miRNA microarray analysis was performed by Kangchen Biotech Co., Ltd. (Shanghai, China). Total RNA was extracted using TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc.) and an miRNeasy mini kit (Qiagen GmbH) according to manufacturer’s protocol. The RNA quantity was measured using the NanoDrop 1000. The samples were labeled using the miRCURY™ Hy3™/Hy5™ Power labeling kit and hybridized on the miRCURY™ LNA Array (v.18.0). Following the washing steps, the slides were scanned using the Agilent Scanner G2505C. Scanned images were imported into GenePix Pro 6.0 software (Molecular Devices, LLC, Sunnyvale, CA, USA) for grid alignment and data extraction. In screening for differentially expressed miRNAs, the threshold was set at fold difference ≥1.5 or ≤0.67, and P<0.05. Hierarchical clustering was performed to demonstrate distinguishable miRNA expression profiling among samples.

RT-qPCR. All assays strictly followed the manufacturer’s protocol. TotalRNA isolation was achieved using TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc.). A PrimeScript RT kit (Takara Biotechnology Co., Ltd., Dalian, Liaoning, China) was used to create the cDNA library. RT-qPCR was performed using SYBR Premix Ex Taq II (Takara Biotechnology, Co., Ltd.) on a LightCycler 480 Real-Time PCR system (Roche Diagnostics, Basel, Switzerland). For qPCR, 1 µg total RNA from each sample was resuspended in 20 µl final volume of reaction buffer. Relative quantification was based on U6 and β-actin controls. All reactions were performed in triplicate and three dishes were prepared in each group in H9c2 cells. The sequences of the primer pairs used were as follows: miR-205 forward, 5’-GGTCTCCTTCACTCCACAGC-3’ and reverse, 5’-TGCTGATTCACTCCAGGTGAGTT-3’; Birc2 forward, 5’-GAAGCCTCACAGATTTG-3’; Birc2 reverse, 5’-CAGCTT GTGTCACAGCTTTCTCT-3’; and reverse, 5’-CAGCG TGGAGTTGCAGTG-3’; caspase-3 forward, 5’-AGAG TACCAAGTGGAGGCCA-3’ and reverse, 5’-AGGAG TACCAAGTGGAGGCCA-3’; Bel-2 associated X protein (Bax) forward, 5’-CTGACATGTGTGGTTGACGCGGC-3’ and reverse, 5’-AGTG CTGAGTGGTGTTGACGCGGC-3’; B-cell lymphoma 2 (Bel-2) forward, 5’-TGGTGGACGACATCGCTG-3’ and reverse, 5’-GAGAAATCAAACAGAGGTGGCC-3’; β-actin forward, 5’-ATAGCACACGGCTTGGCATACAGTAC-3’ and reverse, 5’-CAGAGCATTCTCAATCGAGCTG-3’.

The PCR was performed as follows: 95°C for 30 sec; 40 cycles of 95°C for 5 sec and 60°C for 30 sec; 95°C for 5 sec, 60°C for 60 sec; 50°C for 30 sec. Fold changes relative to control samples were calculated using the 2ΔΔCq method (19).

miR-205 target prediction. For predicting the potential target gene of miR-205, a bioinformatics approach was implemented,
using miRanda (www.microrna.org/microrna/getDownloads.do), TargetScan (version 6.2; www.targetscan.org/) and miRWalk algorithm (version 2.0; zmf.unim.unih-heimberg.de/apps/zmf/mirwalk2/genesup.html). The common prediction results of three databases were used as candidate genes. Birc2, an inhibitor of apoptosis protein, was selected as a predicted target gene of miR-205.

**Dual luciferase reporter gene assay.** The mutant 3’UTR and wild-type 3’UTR of Birc2 were inserted downstream of firefly luciferase in pmiR-Glo to form a luciferase reporter construct. 293T human renal epithelial cells were co-transfected with miR-205 and mutant pmiR-Glo-Birc2-3’UTR or wild-type pmiR-Glo-Birc2-3’UTR (Shanghai GenePharma Co., Ltd., Shanghai, China). Using Lipofectamine 2000, plasmid DNA and miR-205/wild-type 3’UTR of Birc2 were co-transfected into 293T cells. After 24 h, luciferase activity was measured using the Dual-Luciferase Assay system (E1960, Promega Corporation, Madison, WI, USA) and a Multilabel Plate Reader (PerkinElmer, Inc., Waltham, MA, USA). Normalized luciferase activity was calculated as the ratio of Renilla and firefly luciferase activities.

**Western blotting.** SDS lysis buffer was used to extract total protein of rat tissues, and radioimmunoprecipitation assay lysis buffer was used for lysis of H9c2 cells (Beyotime Institute of Biotechnology, Shanghai, China). Proteins (40 µg) were separated by 12% SDS-PAGE and transferred to polyvinylidene fluoride membranes (Roche Diagnostics), blocked using 15% skimmed milk (Yili Group, Inner Mongolia, China). Membranes were incubated overnight at 4°C with primary antibodies against Bcl-2 (mouse monoclonal; 1:2,000 dilution; cat. no. sc-7382; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA), caspase-3 (rabbit polyclonal; 1:500 dilution; cat. no. sc-7145; Santa Cruz Biotechnology, Inc.), Bax (mouse monoclonal; 1:500 dilution; cat. no. sc-7480; Santa Cruz Biotechnology, Inc.), Birc2 (rabbit polyclonal; 1:500 dilution; cat. no. bs-4262R; BIOSS, Beijing, China) and β-actin (mouse monoclonal; 1:1,000 dilution; cat. no. bs-33036m; BIOSS). The blots were then incubated at 37°C for 45 min with a horseradish peroxidase-conjugated goat anti rabbit immunoglobulin G secondary antibody (1:5,000; cat. no. A0208; Beyotime Institute of Biotechnology). A UVP Bioimaging system (BioSpectrum 410; UVP Inc., Upland, CA, USA) and Gel-Pro-Analyzer software version 5.0 (Media Cybernetics, Inc., Bethesda, MD, USA) were used for detection and analysis. For H9c2 cells, three dishes were prepared in each group, and experiments were repeated three times.

**TdT-mediated dUTP nick end labeling (TUNEL) assay.** According to manufacturer’s protocol, a TUNEL kit was used to detect cell apoptosis (cat. no. 11684817910; Roche Diagnostics). H9c2 cells were seeded into 12-well plates; 1 ml of cell suspension was inoculated with 2x10⁵ cells/well. Cells were fixed with 4% paraformaldehyde at room temperature for 30-60 min, and then permeabilized with a 0.1% Triton X-100 solution (50 µl; cat. no. ST779; Beyotime Institute of Biotechnology) in an ice bath for 2-5 min. Cells were then quenched of endogenous peroxidase activity with 3% H₂O₂ (cat. no. 10011218; Sinopharm Chemical Reagent Co., Ltd., Shanghai, China) for 10 min at room temperature away from light, and incubated with the TUNEL reaction mixture (Enzyme solution vs. Label Solution, 1:9) for 1 h at 37°C. Subsequently, cells were stained with 0.8% hematoxylin for 3 min at room temperature. The apoptotic index was evaluated in 5 random fields per section under a fluorescence microscope (magnification, x200) and counted for each group.

**Statistical analysis.** All statistical analyses were performed using SPSS 16.0 software (SPSS, Inc., Chicago, IL, USA). All results are expressed as the mean ± standard deviation. Comparisons among various groups were determined using one-way analysis of variance followed by the post hoc least significant difference test. P<0.05 was considered to indicate a statistically significant difference.

**Results**

**Inhibition of miR-205 in the myocardial tissue of CHF rats following short-term VNS treatment.** As presented in Fig. 1A and B, miR-205 was screened by microarray analysis in our previous study (16), which revealed that the expression level of miR-205 was significantly increased in the CHF-SS group (n=3; P=0.022 vs. SO-SS group) and markedly decreased in the CHF-VNS group (n=4; P=0.026 vs. CHF-SS group) (16). As presented in Fig. 1C, these results were verified in cardiac tissue by RT-qPCR. The expression level of miR-205 in rats of the CHF-SS group was significantly activated compared with the SO-SS group (4.48±1.15 vs. 1.04±0.37, P=0.002). Following short-term VNS, the expression level of miR-205...
was gradually inhibited in CHF-VNS group compared with the CHF-SS group (2.38±0.55 vs. 4.48±1.15, P=0.015).

**Downregulation of miR-205 targeted to increase the expression of Birc2 and further reduce cell apoptosis.** For predicting the potential target gene of miR-205, the present study implemented a bioinformatic analysis using miRanda, TargetScan and miRWalk algorithm. It was demonstrated that Birc2 theoretically included an miR-205 binding site in the 3'UTR (Fig. 2A). Birc2 is one of the inhibitor of apoptosis proteins, and its activation results in cell anti-apoptosis and cytoprotection. Studies have demonstrated that miR-205 accelerates cell apoptosis (20-22); the present study supported this by indicating that miR-205 may regulate Birc2. To verify this hypothesis, the present study cloned the 3'UTR of Birc2 into a pmirGlo-Birc2 vector (Fig. 2B) and co-transfected miR-205 mimics/inhibitor into the vector in 293T cells. Co-transfection of miR-205 inhibited the luciferase activity of the reporter, including wild-type pmiR-Glo-Birc2-3'UTR sequence (0.88±0.03 vs. 1.09±0.01, P<0.001, vs. negative control group; Fig. 2C), but failed to suppress that of mutant pmiR-Glo-Birc2 by dual luciferase reporter gene assay (P>0.05 vs. negative control group; Fig. 2C). These data suggested that miR-205 could directly target the 3'UTR sequences of pmirGlo-Birc2.
Additionally, the protein expression level of Birc2 was significantly suppressed by miR-205 mimic transfection in H9c2 cells (0.62±0.13 vs. 1.02±0.08, P=0.003 vs. NCm group), while the expression was markedly increased by the miR-205 inhibitor (1.28±0.11 vs. 0.99±0.19, P=0.02 vs. NCi group; Fig. 2D). All these findings demonstrated that miR-205 targets and regulates Birc2 protein expression. They also suggested that inhibition of miR-205 expression could serve an anti-apoptotic function by increasing Birc2 expression.

Furthermore, for clarifying the mechanisms of apoptosis, RT-qPCR and western blot analyses were performed to measure the expression levels of Birc2, caspase-3, Bax and Bcl-2. As presented in Fig. 2D, the protein expression levels of caspase-3 and Bax were higher in the miR-205m group compared with the NCm group (1.61±0.18 vs. 1.05±0.13 and 1.48±0.34 vs. 1.03±0.14, P=0.001 and P<0.014, respectively), and were markedly decreased in the miR-205i group compared with the NCi group (0.76±0.04 vs. 1.06±0.21 and 0.63±0.12 vs. 0.98±0.14, P=0.036 and P=0.042, respectively). The protein expression level of Bcl-2 was lower in the miR-205m group (0.67±0.12 vs. 0.99±0.12, P=0.015 vs. NCm group), and was markedly higher in the miR-205i group (1.27±0.2 vs. 1.01±0.09, P=0.037 vs. NC group).

As presented in Fig. 2E, consistent with the western blot results, the mRNA expression levels of caspase-3 and Bax were significantly increased in the CHF-SS group compared with the SO-SS group (2.07±0.13 vs. 1.05±0.4 and 2.63±0.48 vs. 1.01±0.19, P=0.004 and P=0.001, respectively) and were reduced in the CHF-VNS group compared with the CHF-SS group (1.39±0.23 vs. 2.07±0.13 and 1.65±0.15 vs. 2.63±0.48, P=0.023 and P=0.008, respectively). The mRNA expression levels of Birc2 and Bcl-2 were markedly lower in the CHF-SS group compared with the SO-SS group (0.37±0.14 vs. 1.01±0.21 and 0.44±0.05 vs. 1.02±0.22, P=0.002 and P=0.004, respectively) and were increased in the CHF-VNS group compared with the CHF-SS group (0.78±0.1 vs. 0.37±0.14 and 0.87±0.14 vs. 0.44±0.05, P=0.018 and P=0.016, respectively). These data demonstrated that downregulation of miR-205 reduced cell apoptosis.

TUNEL assay was also performed to evaluate apoptosis of H9c2 cells transfected with the miR-205 vector. As presented in Fig. 3, the apoptosis of H9c2 cells was markedly increased in the miR-205m group (13.61±1.44 vs. 8.21±1.56, P<0.001 vs. NCm group), while the apoptosis was markedly reduced in the miR-205i group (4.96±0.70 vs. 8.27±0.94, P<0.001 vs. NCi group).

Anti-apoptosis effect in the myocardial tissue of rats with CHF following short-term VNS treatment. The above studies demonstrated that miR-205 mediates Birc2 to reduce myocardial apoptosis. To further determine the anti-apoptosis effect of short-term VNS treatment in the myocardial tissue of CHF rats, the present measured the expression levels of Birc2, caspase-3, Bax and Bcl-2 using RT-qPCR and western blot analyses in the three experimental groups of rats. As presented in Fig. 4A, the mRNA expression levels of caspase-3 and Bax were significantly increased in the CHF-SS group compared with the SO-SS group (2.07±0.13 vs. 1.05±0.4 and 2.63±0.48 vs. 1.01±0.19, P=0.004 and P=0.001, respectively) and were reduced in the CHF-VNS group compared with the CHF-SS group (1.39±0.23 vs. 2.07±0.13 and 1.65±0.15 vs. 2.63±0.48, P=0.023 and P=0.008, respectively). The mRNA expression levels of Birc2 and Bcl-2 were markedly lower in the CHF-SS group compared with the SO-SS group (0.37±0.14 vs. 1.01±0.21 and 0.44±0.05 vs. 1.02±0.22, P=0.002 and P=0.004, respectively) and were increased in the CHF-VNS group compared with the CHF-SS group (0.78±0.1 vs. 0.37±0.14 and 0.87±0.14 vs. 0.44±0.05, P=0.018 and P=0.016, respectively). As presented in Fig. 4B, consistent with the RT-qPCR results, the protein expression levels of caspase-3 and Bax
were significantly higher in the CHF-SS group compared with the SO-SS group (1.97±0.42 vs. 1.15±0.33 and 2.23±0.68 vs. 1.03±0.03, P=0.041 and P=0.012, respectively). Following short-term VNS, the levels of caspase-3 and Bax were markedly lower in the CHF-VNS group compared with the CHF-SS group (1.10±0.39 vs. 1.97±0.42 and 1.35±0.25 vs. 2.23±0.68, P=0.033 and P=0.042, respectively). The protein expression levels of Birc2 and Bcl-2 in the CHF-SS group were significantly reduced compared with the SO-SS group (0.75±0.04 vs. 0.94±0.06 and 0.62±0.09 vs. 1.12±0.11, P=0.002 and P=0.011, respectively). Following short-term VNS, the level of Birc2 and Bcl-2 were markedly higher in the CHF-VNS group compared with the CHF-SS group (0.97±0.03 vs. 0.75±0.04 and 0.99±0.26 vs. 0.62±0.09, P=0.001 and P=0.034, respectively). All these findings suggested that short-term VNS treatment serves an anti-apoptosis effect in the myocardial tissue of rats following CHF.

Discussion

Heart failure is the dysfunction of contraction and/or diastole, leading to insufficiency of blood circulation in the heart, and is a major cause of mortality from cardiovascular disease (1,23,24). The morbidity of HF is increased with the aging population (25). The clinical treatments of HF have made more progress; however, traditional therapies are insufficient for many patients with HF, who eventually progress to end-stage disease (1). Animal experiments and clinical investigations have reported that VNS treatment improves the cardiac function and prognosis of CHF, and reduces the fatality rate (26-28). Our previous study demonstrated that short-term VNS reduces miR-205 expression in CHF-VNS rats. miR-205 serves a different role in diverse range of tumor cell types (33-36). miR-205 induces inflammation and atherosclerosis in vascular endothelial cells and targets to regulate tissue inhibitor of metalloproteinase 3, which serves
The present study was supported by Liaoning Provincial Science and Technology Department (grant no. 2011404013-7).

References

1. Akat KM, Moore-McGriff D, Morozov P, Brown M, Gogatos T, Correa Da Rosa J, Mihailovic A, Sauer M, Ji R, Ramarathnam A, et al: Comparative RNA-seq-analysing sequence of myocardial and circulating small RNAs in human heart failure and their utility as biomarkers. Proc Natl Acad Sci USA 111: 11151-11156, 2014.

2. Schwartz PJ, De Ferrari GM, Sanzo A, Landolina M, Rordorf R, Raineri C, Campana C, Revera M, Ajmone-Marsan N, Tavazzi L and Ödero A: Long-term vagal stimulation in patients with advanced heart failure: First experience in man. Eur J Heart Fail 10: 884-891, 2008.

3. Sabbah HN, Ilsar I, Zaretsky S, Arostagi S, Wang M and Gupta RC: Vagus nerve stimulation in experimental heart failure. Heart Fail Rev 16: 171-178, 2011.

4. Zannad F, De Ferrari GM, Tuinenburg AE, Wright D, Brugada J, Butter C, Klein H, Stolen C, Meyer S, Stein KM, et al: Chronic vagal stimulation for the treatment of low ejection fraction heart failure: Results of the neural cardiac therapy for heart failure (NECTAR-HF) randomized controlled trial. Eur Heart J 36: 425-433, 2015.

5. Li Y, Xuan YH, Liu SS, Dong J, Luo YJ and Sun ZJ: Short-term vagal nerve stimulation improves left ventricular function following chronic heart failure in rats. Mol Med Rep 12: 1709-1716, 2015.

6. Bartel DP: MicroRNAs: Genomes, biogenesis, mechanism, and function. Cell 116: 287-297, 2004.

7. Wernstinghaus KG and Zamore PD: MicroRNAs: Regulating a change of heart. Circulation 119: 2217-2224, 2009.

8. Cortes KR and Srivastava D: MicroRNA regulation of cardiovascular development. Cire Res 104: 724-732, 2009.

9. Eulalio A, Mano M, Dal Ferro M, Zentilin L, Sinagra G, Zacchigna S and Giacca M: Functional screening identifies miRNAs inducing cardiac regeneration. Nature 492: 376-381, 2012.

10. Latronico MV and Condorelli G: MicroRNAs and cardiac pathology. Nat Rev Cardiol 6: 419-429, 2009.

11. Olivetti G, Abbi R, Quaian F, Kajstura J, Cheng W, Nitahara JA, Quaian E, Di Loreto C, Beltrami CA, Krajeski S, et al: Apoptosis in the failing human heart. N Engl J Med 336: 1131-1141, 1997.

12. Wencker D, Chandra M, Nguyen K, Miao W, Garantziotis S, Factor SM, Shirani J, Armstrong RC and Kitsis RN: A mechanistic role for cardiac myocyte apoptosis in heart failure. J Clin Invest 111: 1497-1504, 2003.

13. Katz MG, Fargnoli AS, Williams RD, Kendell AP, Steuerwald NM and Bridges CR: MiRNAs as potential molecular targets in heart failure. Future Cardiol 10: 789-800, 2014.

14. Xu C, Lu Y, Pan Z, Chu W, Luo X, Lin H, Xiao J, Shan H, Wang Z and Yang B: The muscle-specific microRNAs miR-1 and miR-133 produce opposing effects on apoptosis by targeting HSPE6, HSP70 and caspase-9 in cardiomyocytes. J Cell Sci 120: 3045-3052, 2007.

15. Yang Y, Zheng J, Sun Y, Wu Z, Liu Z and Huang G: MicroRNA-1 regulates cardiomyocyte apoptosis by targeting Bcl-2. Int Heart J 50: 377-387, 2009.

16. Liu SS, Xuan YH, Li Y, Dong J, Luo YJ and Sun ZJ: Short-term vagal nerve stimulation improves chronic heart failure via miR-133a-3p upregulation in a rat model. Int J Clin Exp Pathol 10: 50-60, 2017.

17. Cao JM, Fishbein MC, Han JB, Lai WW, Lai AC, Wu TJ, Czer L, Wolf PL, Denton TA, Shintaku IP, Wright D, Brugada J,下さいの詳細を提供してください。
23. Gaddam KK, Verma A, Thompson M, Amin R and Ventura H: Hypertension and cardiac failure in its various forms. Med Clin North Am 93: 665-680, 2009.

24. Schunnwell CM, Hennersdorf MG and Strauer BE: Hypertension and cardiac failure. Internist (Bert) 48: 909-920, 2007 (In German).

25. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, et al: ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 33: 1787-1847, 2012.

26. Hamann JI, Ruble SB, Stolen C, Wang M, Gupta RC, Rastogi S and Sabbah HN: Vagus nerve stimulation improves left ventricular function in a canine model of chronic heart failure. Eur J Heart Fail 15: 1319-1326, 2013.

27. De Ferrari GM, Crijns HJ, Borggreve M, Milasinovic G, Smid J, Zabel M, Gavazzi A, Sanzo A, Dennen R, Kuschky J, et al: Chronic vagus nerve stimulation: A new and promising therapeutic approach for chronic heart failure. Eur Heart J 32: 847-855, 2011.

28. Premchand RK, Sharma K, Mittal S, Monteiro R, Dixit S, Libbus I, DiCarlo LA, Ardell JL, Rector TS, Amuthur B, et al: Autonomic regulation therapy via left or right cervical vagus nerve stimulation in patients with chronic heart failure: Results of the ANTHEM-HF trial. J Card Fail 20: 808-816, 2014.

29. Li X, Zhang X, Wang T, Sun C, Jin T, Yan H, Zhang J, Li X, Geng T, Chen C, et al: Regulation by bisoprolol for cardiac microRNA expression in a rat volume-overload heart failure model. J Nanosci Nanotechnol 13: 5267-5275, 2013.

30. Tolonen AM, Magga J, Szabó Z, Vittala P, Gao E, Moilanen AM, Ohukainen P, Vainio L, Koch WJ, Kerklé R, et al: Inhibition of Let-7 microRNA attenuates myocardial remodeling and improves cardiac function postinfarction in mice. Pharmacol Res Perspect 2: e00056, 2014.

31. Wong LL, Armugam A, Sepramaniam S, Karolina DS, Lim KY, Lim JY, Chong JP, Ng JY, Chen YT, Chen MM, et al: Circulating microRNAs in heart failure with reduced and preserved left ventricular ejection fraction. Eur J Heart Fail 17: 393-404, 2015.

32. Kuosmanen SM, Hartikainen J, Hippeläinen M, Kokki H, Levonen AL and Tavi P: MicroRNA profiling of pericardial fluid samples from patients with heart failure. PLoS One 10: e0189646, 2015.

33. Wiklund ED, Bramsen JB, Hull T, Dyrvkjot L, Ramanathan R, Hansen TB, Villadsen SB, Gao S, Ostenfeld MS, Borre M, et al: Coordinated epigenetic repression of the miR-200 family and miR-205 in invasive bladder cancer. Int J Cancer 128: 1327-1334, 2011.

34. Schaefer A, Jung M, Mollenkopf HJ, Wagner I, Stephan C, Jentzmik F, Miller K, Lein M, Kristiansen G and Jung K: Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int J Cancer 126: 1166-1176, 2010.

35. Karauyaz M, Zhang C, Liang S, Shroyer KR and Ju J: Prognostic significance of miR-205 in endometrial cancer. PLoS One 7: e35158, 2012.

36. Matsushima K, Isomoto H, Yamaguchi N, Inoue N, Machida H, Nakayama T, Hayashi T, Kunizaki M, Hidaka S, Nagayasu T, et al: MiRNA-205 modulates cellular invasion and migration via regulating zinc finger E-box binding homeobox 2 expression in esophageal squamous cell carcinoma cells. J Transl Med 9: 30, 2011.

37. Son DJ, Kumar S, Takabe W, Kim CW, Ni CW, Alberts-Grill N, Jang IH, Kim S, Kim W, Won Kang S, et al: The atypical mechanosensitive microRNA-712 derived from pre-ribosomal RNA induces endothelial inflammation and atherosclerosis. Nat Commun 4: 3000, 2013.

38. Kim CW, Kumar S, Son DJ, Jang IH, Griendling KK and Jo H: Prevention of abdominal aortic aneurysm by anti-microRNA-712 or anti-microRNA-205 in angiotensin II-infused mice. Arterioscler Thromb Vasc Biol 34: 1412-1421, 2014.

39. Zhang G, Hou X, Li Y and Zhao M: MiR-205 inhibits cell apoptosis by targeting phosphatase and tensin homolog deleted on chromosome ten in endometrial cancer Ishikawa cells. BMC Cancer 14: 440, 2014.

40. Meier P, Finch A and Evan G: Apoptosis in development. Nature 407: 796-801, 2000.

41. LaCasse EC, Baird S, Korneluk RG and MacKenzie AE: The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene 17: 3247-3259, 1998.

42. Warnakulasuriyarachchi D, Cerquozzi S, Cheung HH and Holcik M: Translational induction of the inhibitor of apoptosis HIAP2 during endoplasmic reticulum stress attenuates apoptosis by targeting phosphatase and tensin homolog deleted on chromosome ten in endometrial cancer Ishikawa cells. BMC Cancer 14: 440, 2014.

43. Zhang G, Hou X, Li Y and Zhao M: MiR-205 inhibits cell apoptosis by targeting phosphatase and tensin homolog deleted on chromosome ten in endometrial cancer Ishikawa cells. BMC Cancer 14: 440, 2014.

44. Meier P, Finch A and Evan G: Apoptosis in development. Nature 407: 796-801, 2000.

45. LaCasse EC, Baird S, Korneluk RG and MacKenzie AE: The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene 17: 3247-3259, 1998.

46. Warnakulasuriyarachchi D, Cerquozzi S, Cheung HH and Holcik M: Translational induction of the inhibitor of apoptosis HIAP2 during endoplasmic reticulum stress attenuates cell death and is mediated via an inducible internal ribosome entry site element. J Biol Chem 279: 17148-17157, 2004.

47. Hamanaka RB, Bobrovnikova-Marjon E, Ji X, Liehaber SA and Diehl JA: PERK-dependent regulation of IAP translation during ER stress. Oncogene 28: 910-920, 2009.

48. Kirsch DG, Doseff A, Chau BN, Lim DS, de Souza-Pinto NC, Hansford R, Kastan MB, Lazebnik YA and Hardwick JM: Caspase-3-dependent cleavage of Bcl-2 promotes release of cytochrome c. J Biol Chem 274: 21155-21161, 1999.